Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.85
▼ $0.22 (-3.6%)
Market data updated: 09/19 11:20 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$2.05B
Day Range
$5.82 - $6.18
52-Week Range
$2.99 - $9.75
Beta
—
Next Earnings
02.11.2026
Support
$5.34
Resistance
$7.58
NUVB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+84.5% (1Y)
Strengths: 11/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 699.0%
Growth
Biggest negative driver
Operating margin
Operating margin: -338.7% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
63
Value
55
Momentum
23
Risk
54
Sentiment
100
Fundamental
34
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Nuvation Bio Inc.** has centered on its stock performance and shifting analyst sentiment. The company saw multiple rating upgrades—including an **Overweight** designation from Cantor Fitzgerald and a **Buy** recommendation—while others downgraded it to **Hold** after a sharp 200% rally. Analysts debated its potential for further gains, particularly tied to progress in **NSCLC and glioma** clinical trials, though some expressed caution amid volatility. The company also announced participation in upcoming investor conferences.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Nuvation Bio Inc.. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
27
🎯 Conviction (vs. Emotion)
68
Psychology
85
Fundamentals
34
Technical
23
Valuation
55
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+5%
Market Narrative
53
Fundamental Reality
68
Narrative Gap
-15
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant **herding** state reflects NUVB’s price movement closely tracking peers, suggesting investors are aligning with broader sector trends rather than independent valuation. Euphoria persists despite negative momentum, likely due to elevated valuation relative to historical averages, indicating detached optimism. The narrative-reality gap (-17) hints at a disconnect between market perception and fundamentals, but no clear behavioral bias (e.g., overconfidence) is active. The key question is whether herding will persist or if divergence emerges as sentiment or fundamentals shift.
Updated: 09/09/2026, 06:58 AM
What could change this?
👥 What the crowd believes
"Cantor Fitzgerald Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation"
"Wall Street analysts changed ratings for top stocks. See full list at Benzinga’s analyst ratings page"
"Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?"
"Nuvation Bio (NUVB) downgraded to Hold after a 200% run"
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Thorstein Veblen — 21/100
🗣️ Why do they disagree?
Based on Graham's defensive principles, the model estimates the stock is attractive, reflecting strong fundamentals and margin of safety; similarly, Bagehot's focus on liquidity and Graham's enterprising view also give top scores, indicating deep statistical discount and robust cash availability. Mid‑range scores from Nelson (96) and Lynch (94) suggest a favorable cycle position and growth potential, while investors like Mackay and Smith (both 73) see no crowd mania and a solid long‑term hold case. However, later‑stage investors such as Howard Marks (56/65), Gerald Loeb (57), and Philip Fisher (48) rate the stock lower, citing mixed expectations, moderate risk, and lack of Fisher’s quality‑growth signature. Finally, more speculative and volatility‑focused views (Housel 31, Livermore 21, Veblen 21) highlight concerns about price volatility, negative trends, and growth pursued for its own sake, showing why the overall assessment splits across the spectrum.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 94
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 93
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 73
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 49
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 48
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 25
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-338.7%
Net Margin
-325.3%
EBITDA Margin
-336.0%
ROE
-66.9%
ROA
-34.4%
ROIC
—
EPS
-$0.60
Cash
$164.09M
Total Debt
$52.93M
Current Ratio
6.95
Debt/Equity
0.17
How is Fair Value calculated? →
Current Price
$5.85
Estimated Fair Value (DCF)
-$13,228.68
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-226.78M | $-208.06M |
| 2 | 19.4% | $-270.72M | $-227.86M |
| 3 | 13.8% | $-307.95M | $-237.79M |
| 4 | 8.1% | $-332.97M | $-235.88M |
| 5 | 2.5% | $-341.29M | $-221.82M |
Base FCF (last actual year)
$-181.43M
Terminal Value
$-5.38B
Present Value of Terminal Value
$-3.50B
Enterprise Value
$-4.63B
Net Debt
$-111.15M
Equity Value
$-4.52B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$895.11
Tangible Book Value per Share (Tangible NAV)
$862.27
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
SeekingAlpha · 18.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 16.9.2026
Benzinga · 16.9.2026
Benzinga · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 6.9.2026
TheStreet · 6.9.2026
Benzinga · 4.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 2.9.2026
PR Newswire · 2.9.2026
Yahoo · 31.8.2026
Nuvation Bio Inc. (NUVB) currently has a StockIQ AI score of 50/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NUVB currently scores 50/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
NUVB's technical score is 23/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 699.0%; Earnings per share (EPS) growth: 71.6%; Net income growth: 64.0%.
Based on the real signals StockIQ computed: Operating margin: -338.7% (negative); Net margin: -325.3% (negative); ATR: 5.8% of price.
StockIQ has no recorded dividend payment history for NUVB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 5 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hattersley Gary | Exercise of Derivative Securities | 19.8.2026 | 100,000 | +100,000 | $1.87 |
| Hattersley Gary | Exercise of Derivative Securities | 19.8.2026 | 100,000 | -100,000 | — |
| Hattersley Gary | Open Market Sale | 19.8.2026 | 100,000 | -100,000 | $7.09 |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 39,999 | +39,999 | $2.17 |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 39,999 | -39,999 | — |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 1 | -1 | — |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 1 | +1 | $1.97 |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 54,130 | +39,999 | $2.17 |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 54,131 | +1 | $1.97 |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 662,333 | -39,999 | — |
| Sauvage Philippe | Exercise of Derivative Securities | 15.7.2026 | 499,999 | -1 | — |
| Sauvage Philippe | Exercise of Derivative Securities | 23.6.2026 | 47,668 | -47,668 | — |
| Sauvage Philippe | Exercise of Derivative Securities | 23.6.2026 | 47,668 | +47,668 | $2.17 |
| Sauvage Philippe | Open Market Sale | 23.6.2026 | 47,668 | -47,668 | $6.01 |
| Wentworth Kerry | Exercise of Derivative Securities | 23.6.2026 | 63,000 | -63,000 | — |
| Wentworth Kerry | Open Market Sale | 23.6.2026 | 63,000 | -63,000 | $6.02 |
| Markel Stacy | Exercise of Derivative Securities | 23.6.2026 | 34,620 | -34,620 | — |
| Wentworth Kerry | Exercise of Derivative Securities | 23.6.2026 | 63,000 | +63,000 | $2.93 |
| Markel Stacy | Exercise of Derivative Securities | 23.6.2026 | 90,380 | +90,380 | $1.87 |
| Markel Stacy | Open Market Sale | 23.6.2026 | 125,000 | -125,000 | $6.03 |
| Markel Stacy | Exercise of Derivative Securities | 23.6.2026 | 34,620 | +34,620 | $1.74 |
| Markel Stacy | Exercise of Derivative Securities | 23.6.2026 | 90,380 | -90,380 | — |
| Wentworth Kerry | Exercise of Derivative Securities | 23.6.2026 | 116,000 | +63,000 | $2.93 |
| Wentworth Kerry | Open Market Sale | 23.6.2026 | 53,000 | -63,000 | $6.02 |
| Wentworth Kerry | Exercise of Derivative Securities | 23.6.2026 | 152,250 | -63,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
54,264,998 shares short as of 2026-08-31 · vs. 53,423,972 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
53.9% of trading volume this week was short selling, vs. 60.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology